Published in Proc Natl Acad Sci U S A on August 17, 2006
Cancer immunotherapy comes of age. Nature (2011) 12.35
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Purinergic signaling during inflammation. N Engl J Med (2012) 4.08
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol (2011) 2.94
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One (2008) 2.51
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol (2011) 2.05
Adenosine receptors in regulation of dendritic cell differentiation and function. Blood (2008) 1.91
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest (2011) 1.82
Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov (2013) 1.74
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One (2007) 1.61
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 1.52
Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol (2010) 1.50
A(2B) adenosine receptors in immunity and inflammation. Trends Immunol (2009) 1.48
CD73 Expressed on γδ T Cells Shapes Their Regulatory Effect in Experimental Autoimmune Uveitis. PLoS One (2016) 1.44
Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia (2008) 1.43
Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med (2015) 1.42
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A (2013) 1.32
Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol (2007) 1.32
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol (2008) 1.30
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology (2013) 1.29
Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28
Purinergic signalling and cancer. Purinergic Signal (2013) 1.18
The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol (2012) 1.18
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother (2011) 1.16
Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J (2008) 1.16
Adenosine receptors and cancer. Handb Exp Pharmacol (2009) 1.14
The role of adenosine A2A receptor signaling in bronchiolitis obliterans. Ann Thorac Surg (2009) 1.13
Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J Immunol (2009) 1.13
Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proc Natl Acad Sci U S A (2009) 1.12
Many faces of DAMPs in cancer therapy. Cell Death Dis (2013) 1.11
The role and regulation of human Th17 cells in tumor immunity. Am J Pathol (2012) 1.09
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
Purinergic regulation of the immune system. Nat Rev Immunol (2016) 1.09
CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol (2013) 1.08
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. J Mol Med (Berl) (2013) 1.06
Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res (2014) 1.06
Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol (2014) 1.04
Regulation of leukocyte function by adenosine receptors. Adv Pharmacol (2011) 1.04
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol (2012) 1.03
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res (2014) 1.01
Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol (2012) 1.01
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol (2012) 1.00
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00
Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res (2011) 0.98
Extracellular nucleotide and nucleoside signaling in vascular and blood disease. Blood (2014) 0.97
CD73 promotes tumor growth and metastasis. Oncoimmunology (2012) 0.97
Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials. Nano Today (2011) 0.96
Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation. J Leukoc Biol (2009) 0.96
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res (2014) 0.96
The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol (2010) 0.96
Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice. Shock (2011) 0.96
Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia (2013) 0.96
Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res (2014) 0.95
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
NK1.1 cells and CD8 T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model. Neoplasia (2011) 0.95
Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. J Clin Invest (2015) 0.94
Adenosine receptors in wound healing, fibrosis and angiogenesis. Handb Exp Pharmacol (2009) 0.94
ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis (2014) 0.94
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J Mol Med (Berl) (2014) 0.94
Adenosine receptors and asthma. Handb Exp Pharmacol (2009) 0.93
Adenosine deaminase modulation of telomerase activity and replicative senescence in human CD8 T lymphocytes. J Immunol (2010) 0.93
Adenosine receptors and asthma in humans. Br J Pharmacol (2008) 0.93
Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene (2014) 0.92
Mechanisms of induction of adenosine receptor genes and its functional significance. J Cell Physiol (2009) 0.92
Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother (2010) 0.92
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. Br J Pharmacol (2008) 0.91
Adenosine A2A receptor is involved in cell surface expression of A2B receptor. J Biol Chem (2010) 0.91
From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy. Purinergic Signal (2007) 0.90
In vivo T cell activation in lymphoid tissues is inhibited in the oxygen-poor microenvironment. Front Immunol (2011) 0.90
Embryonic caffeine exposure induces adverse effects in adulthood. FASEB J (2008) 0.90
Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology (2009) 0.90
The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol (2016) 0.89
The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology (2012) 0.89
Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice. PLoS One (2012) 0.89
Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res (2016) 0.88
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol (2016) 0.88
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88
Rebuilding immunity in cancer patients. Blood Cells Mol Dis (2007) 0.88
The adenosinergic immunomodulatory drugs. Curr Opin Pharmacol (2009) 0.88
An in vivo model of melanoma: treatment with ATP. Purinergic Signal (2009) 0.88
Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget (2013) 0.87
Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity. Immunology (2013) 0.87
Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med (Berl) (2013) 0.87
TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol Med (2014) 0.86
Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol (2013) 0.86
Extracellular adenosine signaling in molecular medicine. J Mol Med (Berl) (2013) 0.86
Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma. Epidemiology (2015) 0.85
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (1989) 7.52
Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature (2002) 6.50
Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev (1999) 6.26
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 4.28
Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol (2001) 3.75
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity (2000) 3.07
Angiogenesis and apoptosis. Semin Cancer Biol (2003) 2.86
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood (1997) 2.67
Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med (2004) 2.39
The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res (1997) 1.95
Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem (1997) 1.76
In vitro studies of immune reactions against autochthonous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs. Int J Cancer (1968) 1.73
Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res (1997) 1.67
Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol (1998) 1.62
Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res (2003) 1.60
Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol (1995) 1.52
Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J (2001) 1.49
CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A (2005) 1.45
Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal (2002) 1.45
Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol (2003) 1.38
Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol (2001) 1.27
Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci (1996) 1.25
Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin. J Immunol (2000) 1.23
Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov (1999) 1.21
Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med (2001) 1.20
Role of the extracellular cAMP-adenosine pathway in renal physiology. Am J Physiol Renal Physiol (2001) 1.17
Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res (2002) 1.16
Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer (2002) 1.12
Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway. J Biol Chem (1988) 1.06
T cells take aim at cancer. Proc Natl Acad Sci U S A (2002) 1.04
Study of A(2A) adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A(2A) receptor-unrelated lymphotoxicity. Br J Pharmacol (2000) 0.97
Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol Cell Biol (1988) 0.97
Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J Immunol (2001) 0.94
Immunity against solid tumors? Int J Cancer (2001) 0.91
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Detection of functional DNA motifs via statistical over-representation. Nucleic Acids Res (2004) 6.31
The staufen/pumilio pathway is involved in Drosophila long-term memory. Curr Biol (2003) 4.82
Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 4.28
Animal models of sepsis: setting the stage. Nat Rev Drug Discov (2005) 3.63
Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci (2010) 3.38
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol (2005) 3.21
Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71
Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity (2012) 2.58
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 2.51
Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol (2005) 2.36
Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res (2005) 2.34
Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci (2005) 2.34
Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. Am J Pathol (2010) 2.24
Concern Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest (2012) 2.23
Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest (2003) 2.22
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med (2015) 2.19
Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol (2005) 2.19
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
Differential T cell function and fate in lymph node and nonlymphoid tissues. J Exp Med (2002) 2.14
Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci (2006) 2.14
The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods (2004) 2.13
The posttraumatic stress disorder diagnosis in preschool- and elementary school-age children exposed to motor vehicle accidents. Am J Psychiatry (2008) 2.10
Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci U S A (2006) 1.98
Adenosine and brain function. Int Rev Neurobiol (2005) 1.97
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res (2005) 1.97
A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol (2006) 1.94
Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med (2004) 1.93
Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol (2006) 1.93
GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res (2009) 1.89
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res (2008) 1.84
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol (2006) 1.79
Psychosis pathways converge via D2high dopamine receptors. Synapse (2006) 1.78
Sex hormones and hypertension. Cardiovasc Res (2002) 1.74
Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res (2009) 1.74
Blast exposure in rats with body shielding is characterized primarily by diffuse axonal injury. J Neurotrauma (2011) 1.71
2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res (2006) 1.70
Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 1.70
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods (2009) 1.69
A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J Immunol (2012) 1.67
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One (2007) 1.61
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol (2009) 1.56
Adenosine A(2A) receptor activation prevents progressive kidney fibrosis in a model of immune-associated chronic inflammation. Kidney Int (2011) 1.55
Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol (2002) 1.53
Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem (2005) 1.53
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis (2006) 1.52
Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res (2005) 1.51
Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol (2002) 1.50
A twin study of anxiety-related behaviours in pre-school children. J Child Psychol Psychiatry (2003) 1.48
Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci U S A (2005) 1.48
Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation. Thromb Haemost (2014) 1.48
Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol (2007) 1.48
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol (2011) 1.47
Recombination of retrotransposon and exogenous RNA virus results in nonretroviral cDNA integration. Science (2009) 1.47
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A (2010) 1.46
Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol (2004) 1.45
Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. Leuk Lymphoma (2006) 1.42
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum (2003) 1.41
Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol (2006) 1.41
Conversion of tibolone to 7alpha-methyl-ethinyl estradiol using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry: interpretation and clinical implications. Menopause (2006) 1.38
Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab (2006) 1.37
A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J Immunol (2011) 1.36
Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci (2011) 1.35
Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J Neurotrauma (2007) 1.34
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest (2013) 1.33
Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) (2013) 1.33
Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol (2005) 1.31
Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol (2008) 1.31
Clinical presentation of epithelioid angiomyolipoma. Int J Urol (2007) 1.30
Genetic deletion of A2A adenosine receptors in the striatum selectively impairs habit formation. J Neurosci (2009) 1.29
Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J Gastrointest Surg (2009) 1.28
Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res (2009) 1.28
Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res (2007) 1.27
A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol (2009) 1.27
A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci (2008) 1.27
Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol (2005) 1.26
Maladaptive cognitive appraisals mediate the evolution of posttraumatic stress reactions: A 6-month follow-up of child and adolescent assault and motor vehicle accident survivors. J Abnorm Psychol (2009) 1.26
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem (2012) 1.24
Three-dimensional localization of serine 2808, a phosphorylation site in cardiac ryanodine receptor. J Biol Chem (2007) 1.24
Structure of the absent in melanoma 2 (AIM2) pyrin domain provides insights into the mechanisms of AIM2 autoinhibition and inflammasome assembly. J Biol Chem (2013) 1.24
Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci (2005) 1.24
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol (2008) 1.24
Sleep regulation in adenosine A2A receptor-deficient mice. Neurology (2003) 1.22
Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol (2007) 1.20